

# Evaluation of interferon-induced transmembrane protein-3 (*IFITM3*) rs7478728 and rs3888188 polymorphisms and the risk of pulmonary tuberculosis

MOHAMMAD NADERI<sup>1</sup>, MOHAMMAD HASHEMI<sup>2</sup>, FATEMEH ABEDIPOUR<sup>1</sup>,  
GHOLAMREZA BAHARI<sup>2</sup>, MARYAM REZAEI<sup>2</sup> and MOHSEN TAHERI<sup>3</sup>

<sup>1</sup>Infectious Diseases and Tropical Medicine Research Center; <sup>2</sup>Department of Clinical Biochemistry, School of Medicine;

<sup>3</sup>Genetic of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan 98167, Iran

Received June 3, 2016; Accepted September 21, 2016

DOI: 10.3892/br.2016.763

**Abstract.** The current study aimed to examine the possible association between the interferon-induced transmembrane protein-3 (*IFITM3*) gene polymorphisms and risk of pulmonary tuberculosis (PTB) in a sample population. This case-control study was conducted on 188 PTB patients and 169 healthy subjects. The rs7478728 and rs3888188 variants of *IFITM3* were genotyped using polymerase chain reaction-restriction fragment length polymorphism. The findings showed no significant association between rs7478728 polymorphism and risk of PTB. Regarding rs3888188 polymorphism, the TG genotype as well as G allele significantly increased the risk of PTB [odds ratio (OR)=2.48, 95% confidence interval (CI): 1.42-4.53; P=0.002, and OR=2.26, 95% CI: 1.33-3.86; P=0.003, respectively]. In conclusion, the findings revealed that rs3888188 polymorphism increased the risk of PTB in a sample of Iranian population. Additional investigation with larger sample sizes and different ethnicities are needed to verify our findings.

## Introduction

Tuberculosis (TB), caused by *Mycobacterium tuberculosis* (MTB) infection, is a public health problem globally (1,2). According to the WHO report on the worldwide control of TB, approximately 8.6 million new cases occurred in 2012 (3). Although almost 33% of the population is infected with TB, only 5-10% of infected cases develop active TB (3), which suggests a major role of genetic factors in host immunity.

Interferon- $\gamma$  (IFN $\gamma$ ) is produced and released by host cells in response to the presence of numerous pathogens (4). It plays a key role in macrophage activation during MTB infection (5).

Individuals defective in the genes for IFN $\gamma$  or IFN $\gamma$  receptor (*IFN $\gamma$ R*) have been indicated to be susceptible for mycobacterial infections including MTB (6). Previously, we showed an association between IFN $\gamma$  and *IFN $\gamma$ R* variants and risk of pulmonary TB (PTB) (7,8).

Interferon-induced transmembrane protein-3 (*IFITM3*) is a double transmembrane protein that can be upregulated by IFNs and participates in INF-triggered processes, such as homotypic cell adhesion, anti-proliferative activities in tumor pathogenesis, and the innate immune response to virus infections (9-13). The *IFITM3* gene is mapped to an *IFITM* gene cluster on chromosome 11p15.5 (14). In a genome wide scan, Stein *et al* (15) identified that one of the TB-linked loci was located in this chromosome region. To the best of our knowledge, there is only one report regarding the impact of *IFITM* gene polymorphisms on the risk of TB (16). Therefore, the present study aimed to examine the possible associations between polymorphisms of *IFITM3* gene and susceptibility to PTB in a sample of Iranian population.

## Materials and methods

**Patients.** This case-control study was performed on 188 PTB patients and 169 age- and gender-matched healthy individuals. The enrollment process and study design are described elsewhere (17-23). Briefly, the cases were chosen from PTB patients admitted to a University-Affiliated Hospital (Bou-Ali Hospital, Zahedan, Iran, referral center for TB) with no clinical symptoms or family history of TB. TB was diagnosed by clinical symptoms, posterior-anterior chest radiography, presence of acid-fast-bacilli on a sputum smear, and culturing MTB organisms from a specimen taken from the patient and response to therapy, as described previously (20-23). The project was approved by the local Ethics Committee of the Zahedan University of Medical Sciences and informed consent was obtained from all subjects. DNA was extracted from whole blood samples using the salting out method (24).

**Genotyping.** Genotyping of *IFITM3* rs7478728 and rs3888188 polymorphisms was performed using the polymerase chain reaction (PCR)-restriction fragment length polymorphism

---

**Correspondence to:** Professor Mohammad Hashemi, Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Khalij Fars Boulevard, Zahedan 98167, Iran  
E-mail: mhd.hashemi@gmail.com; hashemim@zaums.ac.ir

**Key words:** tuberculosis, *IFITM3*, polymorphism

Table I. Primer sequences used for the detection of *IFITM3* gene polymorphisms.

Polymorphisms	Sequence (5'→3')	Restriction enzyme	Product size (bp)	Anneling temperature (°C)
rs7478728 C>T	F: TTAGCCCTCAGCCCCTCTTTCGTC R: CTGTTGACAGGAGAGAAGAAGGTT	<i>Alw26I</i>	T allele: 217, 29 C allele: 246	53
rs3888188 T>G	F: CACAGTGAGGGTTATGGGAGAC R: ACTGTTGACAGGAGAGAAGAAGGTT	<i>Hpy188I</i>	G allele: 340, 246 T allele: 586	54

F, forward; R, reverse; *IFITM3*, interferon-induced transmembrane protein-3.

method. The primer sequences are shown in Table I. In each 0.20 ml PCR reaction tube, 1  $\mu$ l of genomic DNA (~100 ng/ml), 1  $\mu$ l of each primer (10  $\mu$ M), 10  $\mu$ l of 2X Prime Taq Premix (Genet Bio Inc., Daejeon, Korea), and 7  $\mu$ l ddH<sub>2</sub>O were added.

Amplification was carried out with an initial denaturation step of 5 min at 95°C followed by 30 cycles of 30 sec at 95°C, annealing at 53°C for rs7478728 and 54°C for rs3888188 for 30 sec and extension at 72°C for 30 sec. Final extension was performed at 72°C for 5 min.

For rs7478728, 10  $\mu$ l of PCR products was digested with *Alw26I* restriction enzyme (Fermentas, Glen Burnie, MD, USA) and then separated by electrophoresis in 2% agarose gels. The C allele was undigested (246-bp), while the T allele was digested and produced 217- and 29-bp fragments (Fig. 1).

For the rs3888188 variant, the PCR products were digested with *Hpy188I* restriction enzyme (Fermentas). The T allele was undigested (586-bp), while the G allele digested and produced 340- and 246-bp fragments (Fig. 2).

To confirm the genotyping quality for each polymorphism, ~20% of random samples were regentyped and the findings confirmed the preceding genotyping results.

**Statistical analysis.** Statistical analysis of the data was performed using the SPSS 20.0 software (IBM SPSS, Armonk, NY, USA). The analysis was performed by the  $\chi^2$  test or independent sample t-test according to the data. The associations between genotypes and PTB were calculated by computing the odds ratio (OR) and 95% confidence interval (CI) from logistic regression analyses. The Hardy-Weinberg equilibrium (HWE) for cases and controls was calculated by  $\chi^2$  test.  $P < 0.05$  was considered to indicate a statistically significant difference.

## Results

**Patient characteristics.** A total of 357 subjects including 188 confirmed PTB patients (73 males, 115 females; ages 50.0±19.5 years) and 169 unrelated healthy subjects (75 males, 94 females; ages 47.9±15.0 years) were assessed. There was no statistically significant difference among the groups regarding gender and age ( $P > 0.05$ ).

**Association between the polymorphisms and PTB risk.** Genotypes and allele frequencies of the *IFITM3* polymorphisms are shown in Table II. Regarding rs7478728 polymorphism, the findings indicated that this variant was not associated with the risk of PTB in codominant (OR=1.32, 95% CI: 0.80-2.17,




Figure 1. *IFITM3* rs7478728 C>T polymorphism using polymerase chain reaction-restriction fragment length polymorphism methods. The C allele was undigested (246-bp), while the T allele was digested by the *Alw26I* restriction enzyme, and 217- and 29-bp fragments were produced. M, DNA marker; lane 1, TT; lanes 2, 4 and 5, CT; and lane 3, CC.




Figure 2. *IFITM3* rs3888188 T>G polymorphism using polymerase chain reaction-restriction fragment length polymorphism methods. The T allele was undigested (586-bp), while the G allele was digested by the *Hpy188I* restriction enzyme and produces 340- and 246-bp fragments. M, DNA marker; lane 1, TT; and lanes 2-4, TG.

$P = 0.337$ , CT vs. CC; OR=2.04, 95% CI: 0.63-6.61,  $P = 0.362$ , TT vs. CC), dominant (OR=1.35, 95% CI: 0.82-2.21,  $P = 0.293$ , CT+TT vs. CC), and recessive (OR=1.65, 95% CI: 0.54-5.02,  $P = 0.538$  TT vs. CC+CT) inheritance model tested. The T allele

Table II. Frequency distribution of *IFITM3* rs7478728 and rs3888188 gene polymorphisms in PTB and controls.

Polymorphisms	Case n (%)	Control n (%)	OR (95% CI)	P-value
rs7478728 C>T				
Codominant				
CC	38 (20.2)	43 (25.4)	1.00	-
CT	141 (75.0)	121 (71.6)	1.32 (0.80-2.17)	0.337
TT	9 (4.8)	5 (3.0)	2.04 (0.63-6.61)	0.362
Dominant				
CC	38 (20.2)	43 (25.4)	1.00	-
CT+TT	150 (79.8)	126 (74.6)	1.35 (0.82-2.21)	0.293
Recessive				
CC+CT	179 (95.2)	164 (97.0)	1.00	-
TT	9 (4.8)	5 (3.0)	1.65 (0.54-5.02)	0.538
Allele				
C	217 (57.7)	207 (61.2)	1.00	-
T	159 (42.3)	131 (38.8)	1.16 (0.86-1.56)	0.377
rs3888188 T>G				
TT	139 (73.9)	148 (87.6)	1.00	-
TG	49 (26.1)	21 (12.4)	2.48 (1.42-4.35)	0.002
GG	0 (0.0)	0 (0.0)	-	-
Allele				
T	327 (87.0)	317 (93.8)	1.00	-
G	49 (13.0)	21 (6.2)	2.26 (1.33-3.86)	0.003

*IFITM3*, interferon-induced transmembrane protein-3; PTB, pulmonary tuberculosis; OR, odds ratio; CI, confidence interval.

Table III. Interaction of *IFITM3* rs7478728 and rs3888188 gene polymorphisms on PTB risk.

rs7478728 C>T	rs3888188 T>G	Case n (%)	Control n (%)	OR (95% CI)	P-value
CC	TT	29 (15.4)	39 (23.1)	1.00	-
CT	TT	104 (55.3)	104 (61.5)	1.34 (0.77-2.34)	0.329
CT	TG	37 (19.7)	17 (10.1)	2.93 (1.38-6.19)	0.006
TT	TT	6 (3.2)	5 (3.0)	1.61 (0.45-5.81)	0.524
CC	TG	9 (4.8)	4 (2.4)	3.03 (0.85-10.80)	0.128
TT	TG	3 (1.6)	0 (0.0)	-	-

*IFITM3*, interferon-induced transmembrane protein-3; PTB, pulmonary tuberculosis; OR, odds ratio; CI, confidence interval.

was not associated with the risk of PTB (OR=1.16, 95% CI: 0.86-1.56, P=0.377) compared to C allele.

Regarding the rs3888188 variant, the results revealed that TG genotype significantly increased the risk of PTB compared to TT genotype (OR=2.48, 95% CI: 1.42-4.35; P=0.002). Similarly, the G allele increased the risk of PTB in comparison with T allele (OR=2.26, 95% CI: 1.33-3.86; P=0.003).

The interaction of the two variants of the *IFITM3* gene was analyzed (Table III) and the findings suggested that the CT/TG genotype significantly increased the risk of PTB compared to CC/TT genotype (P=0.006).

The genotype of *IFITM3* rs7478728 variant in cases and controls was not in HWE ( $\chi^2=54.1$ , P<0.001 and  $\chi^2=43.64$ , P<0.001, respectively). Regarding the *IFITM3* rs3888188 variant, the genotype in controls ( $\chi^2=0.74$ , P=0.389) but not in cases ( $\chi^2=4.22$ , P=0.040) was in HWE.

## Discussion

In the present study, we examined the possible association between *IFITM3* rs7478728 and rs3888188 polymorphisms and the risk of PTB in a sample of Iranian population. Our findings did not support an association between rs7478728

variant and risk of PTB in the population studied. However, we found that TG genotype as well as G allele of rs3888188 polymorphism significantly increased the risk of PTB. There is only one study concerning the possible association between *IFITM3* variants and risk of TB (16). Shen *et al* (16) have found that the rs3888188 G allele increased the risk of pediatric TB (OR=1.30, 95% CI: 1.08-1.56; P=0.039). In addition, they found that the rs7478728 T allele was significantly associated with pediatric TB (OR=1.34, 95% CI: 1.07-1.68; P=0.010), but not after Bonferroni correction (P=0.082). Authors of that study also evaluated the effect of rs3888188 (-204 T>G) variant on *IFITM3* transcription *in vitro* and found that the promoter activity of rs3888188 G allele was lower than that of the T allele. Similarly, peripheral-blood mononuclear cells carrying the rs3888188 GG genotype showed a reduced *IFITM3* mRNA level compared to cells carrying TT or GT genotype. It was concluded that the rs3888188 variant is a functional promoter polymorphism of *IFITM3* that increased the risk of pediatric TB in the Han Chinese population (16). *IFITM3* has been recognized as a key component of the IFN $\gamma$  signaling pathway and down-regulation of *IFITM3* via siRNA significantly reduced the antiviral activities of IFN $\gamma$  by 40-70% (12,13). It is thus a potential candidate gene for TB susceptibility.

*IFITM* proteins are key mediators of the host antiviral response (11-13,25,26). Everitt *et al* (25) showed that mice lacking *IFITM3* gene display fulminant viral pneumonia following infection with a low-pathogenicity influenza virus. Similarly, in an *in vitro* study, an increase in viral replication was observed in the absence of *IFITM3*, and re-introduction of *IFITM3* limited the replication of the influenza A virus (25).

One of the limitations of the present study is the relatively small sample sizes. There is no clear explanation for deviation from HWE for the *IFITM3* rs7478728 variant in our population. The probable reason may be due to genetic drift.

In conclusion, our findings suggest that *IFITM3* rs3888188 polymorphism significantly increased the risk of PTB in a sample of Iranian population. Additional studies with larger sample sizes and diverse ethnicities are necessary to confirm these findings.

## Acknowledgements

The present study was funded by a dissertation research grant (M.D. thesis of FA no. 7265) from the Zahedan University of Medical Sciences. The authors would like to thank the patients and healthy subjects who willingly participated in the study.

## References

- Lin PL and Flynn JL: Understanding latent tuberculosis: A moving target. *J Immunol* 185: 15-22, 2010.
- Oxlade O, Schwartzman K, Behr MA, Benedetti A, Pai M, Heymann J and Menzies D: Global tuberculosis trends: A reflection of changes in tuberculosis control or in population health? *Int J Tuberc Lung Dis* 13: 1238-1246, 2009.
- Zumla A, George A, Sharma V, Herbert N and Baroness Masham of Ilton: WHO's 2013 global report on tuberculosis: Successes, threats, and opportunities. *Lancet* 382: 1765-1767, 2013.
- Stark GR: How cells respond to interferons revisited: From early history to current complexity. *Cytokine Growth Factor Rev* 18: 419-423, 2007.
- Lee J and Kornfeld H: Interferon- $\gamma$  regulates the death of *M. tuberculosis*-infected macrophages. *J Cell Death* 3: 1-11, 2010.
- Ottenhoff TH, Kumararatne D and Casanova JL: Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. *Immunol Today* 19: 491-494, 1998.
- Naderi M, Hashemi M, Rezaei M and Safdari A: Association of genetic polymorphisms of IFNGR1 with the risk of pulmonary tuberculosis in Zahedan, Southeast Iran. *Tuberc Res Treat* 2015: 292505, 2015.
- Hashemi M, Sharifi-Mood B, Nezamdoost M, Moazeni-Roodi A, Naderi M, Kouhpayeh H, Taheri M and Ghavami S: Functional polymorphism of interferon- $\gamma$  (IFN- $\gamma$ ) gene +874T/A polymorphism is associated with pulmonary tuberculosis in Zahedan, Southeast Iran. *Prague Med Rep* 112: 38-43, 2011.
- Seyfried NT, Huysentruyt LC, Atwood JA III, Xia Q, Seyfried TN and Orlando R: Up-regulation of NG2 proteoglycan and interferon-induced transmembrane proteins 1 and 3 in mouse astrocytoma: A membrane proteomics approach. *Cancer Lett* 263: 243-252, 2008.
- Fan J, Peng Z, Zhou C, Qiu G, Tang H, Sun Y, Wang X, Li Q, Le X and Xie K: Gene-expression profiling in Chinese patients with colon cancer by coupling experimental and bioinformatic genome-wide gene-expression analyses: Identification and validation of IFITM3 as a biomarker of early colon carcinogenesis. *Cancer* 113: 266-275, 2008.
- Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, van der Weyden L, Fikrig E, *et al*: The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* 139: 1243-1254, 2009.
- Jiang D, Weidner JM, Qing M, Pan XB, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi PY, *et al*: Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. *J Virol* 84: 8332-8341, 2010.
- Weidner JM, Jiang D, Pan XB, Chang J, Block TM and Guo JT: Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. *J Virol* 84: 12646-12657, 2010.
- Lange UC, Saitou M, Western PS, Barton SC and Surani MA: The fragilis interferon-inducible gene family of transmembrane proteins is associated with germ cell specification in mice. *BMC Dev Biol* 3: 1, 2003.
- Stein CM, Zalwango S, Malone LL, Won S, Mayanja-Kizza H, Mugerwa RD, Leontiev DV, Thompson CL, Cartier KC, Elston RC, *et al*: Genome scan of *M. tuberculosis* infection and disease in Ugandans. *PLoS One* 3: e4094, 2008.
- Shen C, Wu XR, Jiao WW, Sun L, Feng WX, Xiao J, Miao Q, Liu F, Yin QQ, Zhang CG, *et al*: A functional promoter polymorphism of IFITM3 is associated with susceptibility to pediatric tuberculosis in Han Chinese population. *PLoS One* 8: e67816, 2013.
- Hashemi M, Sharifi-Mood B, Rasouli A, Amininia S, Naderi M and Taheri M: Macrophage migration inhibitory factor -173 G/C polymorphism is associated with an increased risk of pulmonary tuberculosis in Zahedan, Southeast Iran. *EXCLI J* 14: 117-122, 2015.
- Naderi M, Hashemi M, Taheri M, Pesarakli H, Eskandari-Nasab E and Bahari G: CD209 promoter -336 A/G (rs4804803) polymorphism is associated with susceptibility to pulmonary tuberculosis in Zahedan, southeast Iran. *J Microbiol Immunol Infect* 47: 171-175, 2014.
- Naderi M, Hashemi M, Pourmontaseri Z, Eskandari-Nasab E, Bahari G and Taheri M: TIRAP rs8177374 gene polymorphism increased the risk of pulmonary tuberculosis in Zahedan, southeast Iran. *Asian Pac J Trop Med* 7: 451-455, 2014.
- Naderi M, Hashemi M, Hazire-Yazdi L, Taheri M, Moazeni-Roodi A, Eskandari-Nasab E and Bahari G: Association between toll-like receptor2 Arg677Trp and 597T/C gene polymorphisms and pulmonary tuberculosis in Zahedan, Southeast Iran. *Braz J Infect Dis* 15: 516-520, 2013.
- Hashemi M, Eskandari-Nasab E, Moazeni-Roodi A, Naderi M, Sharifi-Mood B and Taheri M: Association of CTSZ rs34069356 and MC3R rs6127698 gene polymorphisms with pulmonary tuberculosis. *Int J Tuberc Lung Dis* 17: 1224-1228, 2013.



22. Naderi M, Hashemi M and Amininia S: Association of *TAP1* and *TAP2* Gene Polymorphisms with Susceptibility to Pulmonary Tuberculosis. *Iran J Allergy Asthma Immunol* 15: 62-68, 2016.
23. Bahari G, Hashemi M, Taheri M, Naderi M, Eskandari-Nasab E and Atabaki M: Association of IRGM polymorphisms and susceptibility to pulmonary tuberculosis in Zahedan, Southeast Iran. *Sci World J* 2012: 950801, 2012.
24. Hashemi M, Hanafi Bojd H, Eskandari Nasab E, Bahari A, Hashemzahi NA, Shafieipour S, Narouie B, Taheri M and Ghavami S: Association of Adiponectin rs1501299 and rs266729 Gene Polymorphisms With Nonalcoholic Fatty Liver Disease. *Hepat Mon* 13: e9527, 2013.
25. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, *et al*; MOSAIC Investigators: IFITM3 restricts the morbidity and mortality associated with influenza. *Nature* 484: 519-523, 2012.
26. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, Gaiha GD, Ryan BJ, Donis RO, Elledge SJ, *et al*: IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. *PLoS Pathog* 7: e1002337, 2011.